Ponatinib Demonstrates Greater Clinical Benefit Than Imatinib but With Significantly Higher Care Costs
Key Takeaways:
- Ponatinib is more effective in treating patients with Philadelphia-positive chromosome (PH+) acute lymphoblastic leukemia (ALL) than imatinib. It demonstrated higher life-years (LYs) and quality-adjusted LYs (QALYs) than imatinib, resulting in an additional 3 months of life and an additional 6 months of quality-adjusted life.
- Although ponatinib shows significant cost savings against reference imatinib, it had substantially higher costs than average and weighted generic imatinib, with estimated incremental costs of $147 147 and $128 861, respectively.
- This study’s findings reflect the balance between treatment costs and patient outcomes that providers and payers must navigate in the US health care system.
Tyrosine kinase inhibitors (TKIs) and chemotherapy are the typical treatments for patients with PH+ ALL. Imatinib is the standard TKI used to treat PH+ ALL. However, ponatinib has been shown to be more effective in treating Ph+ ALL, although its safety profile and associated adverse events (AEs) are less favorable than those associated with imatinib.
Since financial value is an important consideration for patients, providers, and payers, this study evaluated the cost-effectiveness of ponatinib relative to reference imatinib, the average cost of several imatinib generics, and the weighted cost of imatinib.
This study performed cost-effectiveness and cost-utility analyses and compared the incremental cost-effective ratio (ICER) and the incremental cost-utility ratio (ICUR) of ponatinib with reference imatinib and average and weighted costs of generic imatinib.
Ponatinib vs Imatinib
This study found that ponatinib, reference imatinib, average generic imatinib, and weighted generic imatinib had cost estimates of $1 097 389, $1 153 413, $950 243, and $968 528, respectively.
Ponatinib had higher LYs and QALYs than for imatinib (3.74 vs 2.15 LY; 3.52 vs 1.68 QALY). Over 60 months, ponatinib had incremental LYs and QALYs of 0.22 and 0.47, meaning ponatinib provides an additional 3 months of life and an additional 6 months of quality-adjusted life.
Compared with reference imatinib, ponatinib was more cost effective, having an estimated $56 024 in cost savings, a decremental -$254 387 per LY gained, and a decremental -$119 796 per QALY gained.
When compared with average and weighted generic imatinib, however, ponatinib had substantial cost increases. Against average imatinib, ponatinib had an incremental cost of $147 147, resulting in an ICER of $668 150 per LY gained, and an ICUR of $314 646 per QALY gained. Against weighted imatinib, ponatinib had an incremental cost of $128 861, resulting in an ICER of $585 122 per LY gained, and an ICUR of $275 546 per QALY gained.
Clinical Implications
Although ponatinib is a more effective TKI than imatinib, its high costs leave patients and care professionals with a value dilemma: whether to choose more affordable therapies with potentially worse outcomes or more expensive treatments with greater clinical benefit.
Ponatinib has more clinical efficiency and is more cost-effective than imatinib, but it has a worse safety profile. Furthermore, it is not nearly as cost-effective as average or weighted generic imatinib.
The authors said, “This [study] highlights the challenge of balancing clinical benefits with economic sustainability, particularly when the modest health gains come at a substantially higher cost.”
Reference
Amamoo RS, Schuerman B, Obeng-Kusi M, Yun S, Erstad B, Abraham I. Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of Philadelphia chromosome-positive acute lymphoblastic leukemia: a value dilemma. J Manage Care Spec Pharm. 2026;32(4):413-421. doi:10.18553/jmcp.2026.32.4.413
